|
Oct 1
|
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
|
|
Oct 1
|
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
|
|
Sep 30
|
Merck & Co. Inc. (MRK): A Strong Investment as KEYTRUDA Sales Drive Revenue Growth
|
|
Sep 30
|
Merck & Co., Inc. (MRK) Projects 21% Upside with $140 Price Target as Keytruda and New Vaccines Drive Growth
|
|
Sep 29
|
Is Merck Stock a Buy?
|
|
Sep 27
|
Merck & Co., Inc. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts
|
|
Sep 26
|
Is Merck & Co., Inc. (MRK) the Best Cheap Beginner Stock to Invest In?
|
|
Sep 26
|
EVAX Process Continues to Garner Interest and Investment
|
|
Sep 26
|
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
|
|
Sep 26
|
Merck & Co. Inc. (MRK): A Good Undervalued Blue Chip Stock to Buy According to Analysts
|
|
Sep 25
|
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
|
|
Sep 25
|
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
|
|
Sep 25
|
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
|
|
Sep 25
|
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
|
|
Sep 25
|
Merck & Co., Inc. (MRK) Poised for 20% Gain, Analysts Say
|
|
Sep 24
|
Company News for Sep 24, 2024
|
|
Sep 24
|
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
|
|
Sep 23
|
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
|
|
Sep 5
|
Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)
|
|
Sep 5
|
MSD and EyeBio launch trial of Restoret for diabetic macular oedema
|